Research programme: vaccines - Cytos Biotechnology

Drug Profile

Research programme: vaccines - Cytos Biotechnology

Alternative Names: C5aQb; CCR5Qb; CYT015-M2AP; CYT017-IL17Qb; DENAP; IL17Qb; IL1aQb; IL5Qb; IL6Qb; MIFQb

Latest Information Update: 13 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytos Biotechnology
  • Class Virus-like particle vaccines
  • Mechanism of Action Cytokine modulators; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Inflammation; Multiple sclerosis; Psoriasis
  • No development reported Dengue; HIV infections
  • Discontinued Atherosclerosis; Cancer; Creutzfeldt-Jakob disease; Hepatitis B; Hypersensitivity; Osteoporosis; Systemic lupus erythematosus

Most Recent Events

  • 13 May 2014 Research programme: vaccines - Cytos Biotechnology is available for licensing as of 05 May 2014.
  • 18 Aug 2011 Suspended - Preclinical for Inflammation in Switzerland (unspecified route)
  • 18 Aug 2011 Suspended - Preclinical for Multiple sclerosis in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top